ROCK
Rho-associated protein kinase; Rho-associated kinase; Rho-kinase; ROK
ROCK (Rho-associated protein kinase) is a kinase belonging to the AGC (PKA/ PKG/PKC) family of serine-threonine kinases. ROCKs (ROCK1 and ROCK2) occur in mammals, zebrafish, Xenopus, invertebrates and chicken. Human ROCK1 has a molecular mass of 158 kDa and is a major downstream effector of the small GTPase RhoA. Mammalian ROCK consists of a kinase domain, acoiled-coil region and a Pleckstrin homology (PH) domain, which reduces the kinase activity of ROCKs by an autoinhibitory intramolecular fold if RhoA-GTP is not present. ROCK plays a role in a wide range of different cellular phenomena, as ROCK is a downstream effector protein of the small GTPase Rho, which is one of the major regulators of the cytoskeleton.
ROCK Isoform Specific Products
All Product Categories
-
ROCK Related Products (197)
Related Products (197)
-
Antibodies (12)
-
ROCK Isoform Comparison
-
ROCK-IN-9
0 ImagesCat. No.: HY-156593CAS No.: 2643334-76-1ROCK-IN-9 (Compound T345) is a ROCK inhibitor. ROCK-IN-9 shows cytotoxicity in HepG2 cell, with an IC50 of 40.8 μM. ROCK-IN-9 has good pharmacokinetic properties in mice, and shows high in vivo exposure and oral bioavailability at lower doses.
-
ROCK2-IN-15
0 ImagesCat. No.: HY-185667CAS No.: 3060005-08-2ROCK2-IN-15 (2-11) is a ROCK2 inhibitor with selective activity against Rho-kinase mediated phosphorylation of myosin light chain phosphates .ROCK2-IN-15 can be used for the research of cardiovascular diseases, pulmonary diseases, inflammatory diseases, neurological diseases, proliferative diseases .
-
ROCK2-IN-13
0 ImagesCat. No.: HY-179498ROCK2-IN-13 is a selective ROCK2 inhibitor. ROCK2-IN-13 reduces nuclear expression by disrupting the interaction of ROCK2 with transcriptional co activators p300> and PGC 1α, repressing oncogenic transcription. ROCK2-IN-13 activates FOXO1 driven PTEN expression, leading to suppression of the PI3K/Akt pathway, induction of G2/M cell cycle arrest, and promotion of apoptosis. ROCK2-IN-13 ablates the nuclear transcriptional function of ROCK2 that sustains oncogenic signaling and restores the tumor suppressive PTEN/FOXO1 axis. ROCK2-IN-13 can be used for prostate cancer reseach.
-
SB772077B
0 ImagesCat. No.: HY-123958CAS No.: 785774-34-7SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research.
-
HA-100 hydrochloride
0 ImagesCat. No.: HY-100984ACAS No.: 141543-63-7
-
SR-3677 dihydrochloride
0 ImagesCat. No.: HY-13300ACAS No.: 1781628-88-3SR-3677 dihydrochloride (compound 5) is a potent and selective ROCK-I and ROCK-II inhibitor with an IC50 values of 56 nM and 3 nM.
-
AR-13503 (Standard)
0 ImagesCat. No.: HY-12798CRCAS No.: 2309668-15-1Synonyms: AR-13324 M1 metabolite (Standard)Fluanisone (Standard) is the analytical standard of Fluanisone. This product is intended for research and analytical applications. Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia.
-
ROCK-IN-D1
0 ImagesCat. No.: HY-123484CAS No.: 1219721-73-9ROCK-IN-D1 serves as a highly effective and selective inhibitor of ROCK.
-
ROCK2-IN-5
0 ImagesCat. No.: HY-145294CAS No.: 3031515-48-4ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation.
-
(Rac)-NRL-1049 dihydrochloride
0 ImagesCat. No.: HY-162596ACAS No.: 863638-93-1Synonyms: (Rac)-BA-1049(Rac)-NRL-1049 is the racemic mixture of NRL-1049 (BA-1049 (free base)) (HY-162596). NRL-1049 is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations.
-
CCG-232964
0 ImagesCat. No.: HY-130011CAS No.: 2349373-70-0CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression.
-
5-Nitro-1H-indazole-3-carbonitrile
0 ImagesCat. No.: HY-W047432CAS No.: 90348-29-1Synonyms: DL08055-Nitro-1H-indazole-3-carbonitrile (DL0805) is a Rho kinase(ROCK) inhibitor with an IC50 of 6.67 μM for ROCK-I. 5-Nitro-1H-indazole-3-carbonitrile reduces Norepinephrine (HY-13715)-induced transient contraction and inhibits contraction induced by increasing external calcium in the endothelium-denuded rings of rat models. 5-Nitro-1H-indazole-3-carbonitrile has a vasorelaxant activity but high toxicity. 5-Nitro-1H-indazole-3-carbonitrile can be used for cardiovascular diseases, especially hypertension research.
-
LASSBio-2389
0 ImagesCat. No.: HY-181583CAS No.: 2671377-38-9
-
HA-100 dihydrochloride
0 ImagesCat. No.: HY-12880CAS No.: 210297-47-5
-
WF-536
0 ImagesCat. No.: HY-118837CAS No.: 539857-64-2
-
RX-044
0 ImagesCat. No.: HY-187204RX-044 is a ROCK1/ROCK2 inhibitor with ROCK1 IC50 10.01 nM and ROCK2 IC50 9.68 nM, and demonstrates kinase selectivity. RX-044 induces reversible cell retraction, modulates cytoskeletal organization via F-actin depolymerization, inhibits cell contractility, and attenuates TGF-β2-induced cell migration. RX-044 preserves retinal ganglion cell survival, restores electroretinography responses, and ameliorates histopathological changes. RX-044 lowers intraocular pressure in a mouse ocular hypertension model. RX-044 shows no cytotoxicity in target cells. RX-044 exhibits initial ocular irritation that subsides with extended dosing. RX-044 can be used for the research of glaucoma.
-
ROCK2-IN-14
0 ImagesCat. No.: HY-181576CAS No.: 3115784-59-0ROCK2-IN-14 is an orally active, selective ROCK2 inhibitor (IC50=4.8 nM) with 212-fold selectivity over ROCK1 (IC50=1.01 μM). By inhibiting the ROCK2/S100A9 signaling pathway, ROCK2-IN-14 downregulates S100A9 expression, inhibits NM2 phosphorylation and restores cytoskeletal abnormalities. Furthermore, ROCK2-IN-14 reduces inflammatory cytokine levels, alleviates skin inflammation and exerts anti-inflammatory activity. ROCK2-IN-14 also significantly inhibits ear thickening in a mouse model of atopic dermatitis (AD), and decreases the levels of IgE, TNF-α, IL-6 and TSLP. ROCK2-IN-14 can be used for research on atopic dermatitis.
-
ROCK-IN-11
0 ImagesCat. No.: HY-W295201CAS No.: 445267-51-6
